Winton Group LTD Voyager Therapeutics, Inc. Transaction History

Winton Group LTD

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	SELL	$7.42 - $10.54 $285,551 - $405,621	-38,484 Reduced 51.65%	36,027 $284,000
Q1 2024 May 14, 2024	BUY	$7.15 - $10.84 $207,199 - $314,132	28,979 Added 63.65%	74,511 $693,000
Q4 2023 Feb 12, 2024	SELL	$6.28 - $8.81 $25,710 - $36,068	-4,094 Reduced 8.25%	45,532 $384,000
Q3 2023 Nov 13, 2023	BUY	$7.55 - $11.25 $190,894 - $284,445	25,284 Added 103.87%	49,626 $384,000
Q2 2023 Aug 14, 2023	BUY	$6.94 - $13.99 $168,933 - $340,544	24,342 New	24,342 $278,000
Q4 2021 Feb 10, 2022	SELL	$2.47 - $5.55 $59,988 - $134,792	-24,287 Closed	0 $0
Q3 2021 Oct 28, 2021	BUY	$2.63 - $4.12 $15,937 - $24,967	6,060 Added 33.25%	24,287 $64,000
Q2 2021 Aug 10, 2021	BUY	$3.94 - $5.44 $71,814 - $99,154	18,227 New	18,227 $75,000
Q1 2020 May 11, 2020	SELL	$6.8 - $14.66 $247,452 - $533,477	-36,390 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$12.82 - $16.85 $466,519 - $613,171	36,390 New	36,390 $508,000

131

34.9M

39.7K

34.6K

Ticker VYGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,647,600
Market Cap $215M
Description
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyo...

Get notified when there are updates to the investment portfolio of Winton Group LTD, based on Form 13F filings with the SEC.

Stay updated on Winton Group LTD with notifications on news.